344 related articles for article (PubMed ID: 16154196)
1. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
[TBL] [Abstract][Full Text] [Related]
2. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
[TBL] [Abstract][Full Text] [Related]
3. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.
Loftus JV; Sultan MB; Pleil AM;
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7498-505. PubMed ID: 21896838
[TBL] [Abstract][Full Text] [Related]
4. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Adamis AP; Altaweel M; Bressler NM; Cunningham ET; Davis MD; Goldbaum M; Gonzales C; Guyer DR; Barrett K; Patel M;
Ophthalmology; 2006 Jan; 113(1):23-8. PubMed ID: 16343627
[TBL] [Abstract][Full Text] [Related]
5. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Wroblewski JJ; Wells JA; Gonzales CR
Am J Ophthalmol; 2010 Jan; 149(1):147-54. PubMed ID: 19875087
[TBL] [Abstract][Full Text] [Related]
6. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Wroblewski JJ; Wells JA; Adamis AP; Buggage RR; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Altaweel MM;
Arch Ophthalmol; 2009 Apr; 127(4):374-80. PubMed ID: 19365011
[TBL] [Abstract][Full Text] [Related]
7. Pegaptanib for neovascular age-related macular degeneration.
Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
12. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
[TBL] [Abstract][Full Text] [Related]
13. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
15. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
[TBL] [Abstract][Full Text] [Related]
16. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
17. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS;
Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
